Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020

NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. PRVL ("Prevail" or the "Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the upcoming presentation of three abstracts at the 16^th Annual WORLDSymposium™, taking place February 10-13, 2020, in Orlando, FL.  The abstracts include preclinical data from Prevail's programs PR001 for neuronopathic Gaucher disease and PR006 for frontotemporal dementia with GRN mutation.  

Two abstracts will be presented during the poster session on Monday, February 10^th from 4:30 p.m. to 6:30 p.m. ET.  Poster information is as follows:

Abstract Title: Gene therapy PR006 increased progranulin levels and improved lysosomal related phenotypes in model systems (poster #52)
Presenter: Laura Heckman, Ph.D.

Abstract Title: Gene therapy PR001 increased GCase activity and improved neuronopathic Gaucher disease phenotypes in mouse models (poster #159)
Presenter: Laura Heckman, Ph.D.

One abstract will be presented during the Contemporary Forum session on Thursday, February 13^th at 1:30 p.m. ET. Oral presentation information is as follows:

Abstract Title: Gene therapy PR006 increased progranulin levels and improved lysosomal related phenotypes in model systems
Presenter: Asa Abeliovich, M.D., Ph.D.

In addition to its presentations at WORLDSymposium, on Wednesday, February 12^th at 8:30 p.m. ET, management will be hosting a presentation by Professor Ari Zimran, M.D., a key opinion leader in the field of neuronopathic Gaucher disease, on "Unmet Needs and Emerging Therapeutic Options for Neuronopathic Gaucher Disease", with a roundtable discussion to follow.  A recording of this event and accompanying slides will be made available immediately following its conclusion and can be found under "Events and Presentations" in the Investors & Media section of the company's website, www.prevailtherapeutics.com. The webcasts will be archived for 90 days following the presentation.

About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson's disease with a GBA1 mutation (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutation (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson's with GBA and OrbiMed, and is headquartered in New York, NY.

Forward-Looking Statements Related to Prevail
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning Prevail's ability to develop meaningful therapeutic advances for patients with neurodegenerative diseases. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevail's novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevail's gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; and the fact that gene therapies are novel, complex and difficult to manufacture. These and other risks are described more fully in Prevail's filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2019, filed with the SEC on November 12, 2019, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Katie Engleman
1AB
katie@1ABmedia.com

Investor Contact:
investors@prevailtherapeutics.com